Safinamide

Quality products?make an important contribution to long-term revenue and profitability. Buy Good Quality Safinamide 133865-89-1 with a minimum purity of 99%

1.What is the Safinamide ?

Safinamide (133865-89-1) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A.1?Displays anticonvulsant activity2?and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models3. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade.4?A novel therapeutic for Parkinson’s disease with multiple modes of action.5?Effective as an add-on to dopamine agonist therapy in early Parkinson’s.6

2.What is the CAS number for Safinamide ?

The CAS number of Safinamide is 133865-89-1.

3.What are another words for Safinamide ?

Synonyms?for?Safinamide 133865-89-1:Propanamide,2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-;(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide;FCE 26743;Safinamide;2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide;

4.What is Safinamide (133865-89-1) used for?

Used in Pharmaceutical Industry:
Safinamide is used as a therapeutic agent for the treatment of Parkinson's disease. It is effective as an add-on to dopamine agonist therapy in early Parkinson's, providing multiple modes of action to manage the symptoms and progression of the disease.

In 2003 positive preliminary results from a phase II trial of safinamide in epilepsy were announced. This open-labeled study was initiated to assess tolerability and drug–drug interaction (DDI) of safinamide in 48 patients with uncontrolled seizures that had already been treated with up to three other antiepileptic drugs. Starting with an initial oral dose of 50mg d?1, safinamide was increased every two weeks up to 300 mg d?1 or to the maximum tolerated dose. An interim analysis of the first 29 patients who completed the study showed excellent tolerability. In this group, no DDI was noted at any of the tested doses in that safinamide did not alter the kinetics of the other antiepileptic drugs. In this interim analysis safinamide was shown to be well tolerated in patients with medically intractable seizures. No serious AEs occurred in the study. Even though the study was not designed and powered to provide proof of efficacy, the sponsor reported that preliminary data showed a significant reduction in median seizure frequency from 50mg progressing up to the highest dose. In 2005 safinamide was administered to a total of 10 patients with RLS that were enrolled into a single-center, phase II open-labeled pilot study. Each patient was administered safinamide (100 mg d?1) at bedtime for 2 weeks. A significant improvement in all efficacy parameters studied was observed when patients received safinamide. RLS is a neurological disorder characterized by jerky movements of the lower extremities that appear mostly in the evening and during sleep. As reported in a press release, safinamide was also found to be well tolerated and did not exhibit any clinically relevant side effects, but no study results have been published.

InChI:InChI=1/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1

Relevant articles related to Safinamide:

5.Buy Safinamide with the best price .

Shijiazhuang Lianhua Chemicals Co.,Ltd. is a quality supplier of Safinamide. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Safinamide 133865-89-1.